Oxybutynin lowers elevated renal pelvic pressures in a rat congenital unilateral hydronephrosis.
We investigated whether oxybutynin could lower elevated renal pelvic pressures measured in a rat with an inbred unilateral congenital hydronephrosis. Simultaneous renal pelvic and bladder pressures were measured in 8 hydronephrotic rats and compared to those of 10 hydronephrotic rats treated with intravenous injection of 1.6 mg./kg. oxybutynin. Pressures were recorded at different urinary flow rates and during bladder filling and emptying. Hydronephrotic rats not given oxybutynin showed significantly higher renal pelvic pressures (e.g. p-bladder at 50% capacity = 8.9 +/- 3.1 cm. H2O, corresponding p-pelvis = 20.8 +/- 2.1 at very high urinary flow rates) than rats treated with oxybutynin. The latter had renal pelvic pressures similar to rats with normal non-hydronephrotic kidneys (e.g. p-bladder at 50% capacity = 10.1 +/- 3.5 cm. H2O, corresponding p-pelvis = 6.3 +/- 1.1 at very high urinary flow rates). Renal pelvic pressures were, moreover, lower than corresponding bladder pressures in contrast to the untreated hydronephrotic pelvic pressure that exceeded bladder pressure. This effect of oxybutynin in lowering elevated renal pelvic pressures in the obstructed kidney has not been described before and suggests a possible role for oxybutynin in this condition.
Fichtner
J
J
Department of Urology, Stanford University School of Medicine, California, USA.
Boineau
F G
FG
Lewy
J E
JE
Shortliffe
L M
LM
D000818:Animals; D018680:Cholinergic Antagonists / Q000494:pharmacology*; D006869:Hydronephrosis / Q000151:congenital / Q000503:physiopathology*; D007682:Kidney Pelvis / Q000187:drug effects* / Q000503:physiopathology*; D008297:Male; D008333:Mandelic Acids / Q000494:pharmacology*; D011312:Pressure; D051381:Rats; D017208:Rats, Wistar
D018680:Cholinergic Antagonists; D008333:Mandelic Acids; C005419:oxybutynin